Equillium, Inc. $EQ

What the company doesAI summary of filing

Equillium is a preclinical-stage biotechnology company developing novel therapies for severe autoimmune and inflammatory disorders. The company's lead program is EQ504, a potent and selective aryl hydrocarbon receptor modulator currently in preclinical development, which it intends to advance into clinical studies beginning in mid-2026 for the treatment of ulcerative colitis and other gastrointestinal diseases, with potential expansion to inflammatory lung diseases. The company also acquired EQ302, a first-in-class selective inhibitor of IL-15 and IL-21 for oral delivery in preclinical development for celiac disease and other gastrointestinal indications. Equillium is pre-revenue and relies on equity financing to fund operations; the company raised approximately $30 million in August 2025 and $35 million in March 2026, and expects cash to be sufficient to fund operating expenses into 2029. [10-K 2026-03-25]

Segments: EQ504 (AhR modulator), EQ302 (IL-15 and IL-21 inhibitor)